ClinicalTrials.gg
RecruitingNCT07019662CLOSE-ECMOUpdated Nov 6, 2026

Comparing a Suture-based System for the Removal of Arterial and Veinous ECMO Cannulas to the Standard Approach

An interventional study of Decannulation with a medical device and Decannulation using surgical removal or manual compression in VA-ECMO, sponsored by IHF GmbH - Institut für Herzinfarktforschung. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by IHF GmbH - Institut für Herzinfarktforschung · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
102
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Background:

Patients with severe heart and lung failure may be treated with VA-ECMO (veno-arterial extracorporeal membrane oxygenation), a life-support machine that temporarily takes over the function of the heart and lungs. To connect the patient to ECMO, large tubes (cannulas) are inserted into major blood vessels in the groin area.

When the patient no longer needs ECMO, these cannulas must be removed - a process known as decannulation. Closing the artery after removing the cannula is a critical step and can be associated with complications such as bleeding, vessel injury, or blood clots.

Currently, there are different methods to close the artery:

  • Surgical closure: open surgery to directly suture the artery
  • Manual compression: pressing on the artery to stop bleeding
  • Vascular closure devices (VCDs): special tools that close the artery through the skin

There is no clear standard yet on which method is safest and most effective for ECMO patients.

Purpose of the Study:

The study aims to determine whether using a vascular closure device is as safe and effective as the current standard methods for femoral artery closure after VA-ECMO.

Study Design:

This is a randomized controlled trial. Patients who are scheduled for decannulation after VA-ECMO support will be randomly assigned to one of two groups:

  • Intervention Group: Patients receive a vascular closure device to seal the artery (Abbott Perclose™ ProStyle™ Suture-Mediated Closure System).
  • Control Group: Patients receive standard care, which may be either:

    • Manual compression, or
    • Surgical closure, depending on the treating physician's judgment and the patient's condition.

This allows for a real-world comparison of the Closure Device method to current clinical practice.

02

Conditions studied

  • VA-ECMO
03

In context

Lead sponsor

IHF GmbH - Institut für Herzinfarktforschung is the lead sponsor of 16 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 Years
  • Femoral placement of VA-ECMO with peripheral, percutaneous cannulation
  • Arterial puncture site above the femoral bifurcation
  • Cannula size must match or be smaller than the maximally licensed diameter for Perclose™ ProStyle™ (26 F (French) outer diameter arterial and 29 F outer diameter veinous)
  • Patients must be eligible for either the Perclose™ ProStyle™ device or one of the two guideline-compliant alternatives for ECMO cannula removal (manual compression or surgical closure) according to the investigator's judgment.
  • Initial arterial and/or venous puncture for ECMO cannulation was performed using ultrasound guidance with corresponding documentation available in the patient record.

Exclusion criteria

Exclusion Criteria:

  • Severe calcification
  • Surgical cannulation
  • Ongoing Infection of the ECMO site
  • Any patient who does not fullfil the eligibility criteria for the use of the study device according to its current Instructions for Use (IFU), including known , limitations or warnings.
  • Participation in another interventional clinical trial.
  • Patients who are pregnant (assessed by clinical routine testing) or lactating.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
102 participants (estimated)

Study arms

  • Experimental
    Decannulation using the Perclose™ ProStyle™

    Device: Decannulation with a medical device

  • Active comparator
    Standard of Care: Decannulation using surgical removal or manual compression

    Procedure: Decannulation using surgical removal or manual compression

Interventions

  • DeviceDecannulation with a medical device

    Wound Closure with a medical device

  • ProcedureDecannulation using surgical removal or manual compression

    Wound closure using surgical removal or manual compression

06

What researchers measure

Primary outcomes

  1. Incidence of a combined vessel-orientated clinical endpoint (VOCE)

    Time frame: within 48 hours post ECMO removal

Secondary outcomes

  1. Length of ICU (intensive care unit) stay post ECMO removal

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  2. Length of hospital stay post ECMO removal

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  3. Time to mobilization post ECMO removal

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  4. Costs of hospital stay

    Time frame: Prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  5. Incidence of Bleeding requiring transfusion (BARC3a)

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  6. Vascular complication requiring surgical or interventional therapy

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  7. Wound infection requiring antibiotic use or surgical debridement

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  8. Rate of pseudoaneurysms as detected by vascular Ultrasound

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  9. Rate of veinous thrombosis in the lower vessels as detected by vascular ultrasound

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

  10. Rate of arterial thrombosis in the lower vessel as detected by vascular ultrasound

    Time frame: At 48 hours post-ECMO and prior to hospital discharge, but no longer than 30 days after ECMO decannulation, whichever occurs first

07

Study locations

2 of 2 sites recruiting
  • Universitäres Herz- und Gefäßzentrum Frankfurt ZIM - Med. Clinic 3 - Cardiology and Angiology
    Frankfurt, Germany
    Recruiting
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz - Zentrum für Kardiologie
    Mainz, Germany
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Feb 2027, 16 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 26, 2025
First posted
Jun 13, 2025
StartActual
Oct 27, 2025
Primary completionEst.
Feb 2027
CompletionEst.
Sep 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07019662
Lead sponsor
IHF GmbH - Institut für Herzinfarktforschung
Responsible party
Sponsor
First posted
Jun 13, 2025
Start date
Oct 27, 2025
Primary completion
Feb 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Jelena Weller
Contact
close-ecmo@ihf.de
+49 62159577216
Marcel Kunadt, Dr.
Contact
Robert Stöhr, PD Dr. Dr.
principal investigator · Universitäres Herz- und Gefäßzentrum Frankfurt ZIM - Med. Clinic 3 - Cardiology and Angiology

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion